Metastatic Prostate Cancer
This e-course will comprise three presentations that provide comprehensive state-of-the-art information on currently available therapies for hormone-naïve prostate cancer (HNPC) and castration-resistant prostate cancer (CRPC).
|Organiser||European School of Urology (ESU)|
|Duration||Approx. 60 minutes|
The therapies will include androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPI), chemotherapy, radioligand, and poly (ADP-ribose) polymerase (PARP) inhibitors.
The e-course aims to enable participants in optimising treatment combinations and sequences in metastatic prostate cancer at all disease stages.
Prof. B. Tombal (BE)
Dr. C. Thibault (FR)
Prof. Dr. C. Gratzke (DE)
Contact our organiser
European School of Urology (ESU)